Wall Street Wizardry
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Wall Street Wizardry

World News

Prince Frederik of Luxembourg dies from rare disease

by admin March 10, 2025
March 10, 2025
Prince Frederik of Luxembourg dies from rare disease

Prince Frederik of Luxembourg has died after a lifelong battle with a rare genetic disorder known as POLG mitochondrial disease.

He passed away on March 1 in Paris, his family announced on the website of the POLG Foundation, which Frederik started in 2022.

“It is with a very heavy heart that my wife and I would like to inform you of the passing of our son, The POLG Foundation Founder and Creative Director, Frederik,” his father Prince Robert of Luxembourg wrote.

The foundation describes POLG as a “genetic mitochondrial disorder that robs the body’s cells of energy, in turn causing progressive multiple organ dysfunction and failure.”

It said the disease has no treatment or cure.

“Frederik and the POLG Foundation … are committed to finding therapies and a cure to save other patients from suffering what Frederik and our family have endured,” his father wrote.

Prince Frederik died a day after Rare Disease Day. He was in his early 20s.

This post appeared first on cnn.com

previous post
Nepal’s authoritarian king was ousted 19 years ago. Now many want the monarchy back
next post
Canada’s Liberal Party chooses Mark Carney to succeed Justin Trudeau

Related Posts

China resumes seafood imports from some Japan regions

June 30, 2025

At least 16 dead, including 6 children, in...

April 5, 2025

Russia steps up offensive across the front line...

April 9, 2025

Freed Israeli hostages did not know their loved...

February 9, 2025

Convicted Italian cardinal pulls out of conclave to...

April 29, 2025

Israel completes withdrawal from key road dividing Gaza...

February 10, 2025

Israeli soldiers reveal systematic destruction of Palestinian property...

April 8, 2025

Japan’s annual births fall to record low as...

June 5, 2025

Far from being cowed by US airstrikes, Yemen’s...

April 6, 2025

The tide is turning on shark nets at...

April 9, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 26, 2025
    • 2

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 3

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 4

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 5

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 6

      US security contractor will take charge of key checkpoint in Gaza as Israeli forces withdraw

      January 25, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • Terms and Conditions
    • Privacy Policy

    Disclaimer: wallstreetwizardry.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 wallstreetwizardry.com | All Rights Reserved